Antonin Lévy

7.6k total citations · 1 hit paper
266 papers, 4.7k citations indexed

About

Antonin Lévy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Antonin Lévy has authored 266 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Pulmonary and Respiratory Medicine, 109 papers in Oncology and 70 papers in Surgery. Recurrent topics in Antonin Lévy's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (36 papers). Antonin Lévy is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (36 papers). Antonin Lévy collaborates with scholars based in France, United States and United Kingdom. Antonin Lévy's co-authors include Éric Deutsch, Cyrus Chargari, C. Le Péchoux, Jean‐Charles Soria, Nicolas Magné, Yungan Tao, Christophe Massard, Louis D. Van de Kar, Pierre Blanchard and Peter A. Rittenhouse and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Molecular and Cellular Biology.

In The Last Decade

Antonin Lévy

246 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis

2016 307 citations Dario Callegaro, Rosalba Miceli et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Antonin Lévy

Since Specialization

Citations

This map shows the geographic impact of Antonin Lévy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonin Lévy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonin Lévy more than expected).

Fields of papers citing papers by Antonin Lévy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonin Lévy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonin Lévy. The network helps show where Antonin Lévy may publish in the future.

Co-authorship network of co-authors of Antonin Lévy

This figure shows the co-authorship network connecting the top 25 collaborators of Antonin Lévy. A scholar is included among the top collaborators of Antonin Lévy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonin Lévy. Antonin Lévy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unresectable stage III non-small-cell lung cancer: state of the art and challenges 2025 ·Nature Reviews Clinical Oncology ·Jordi Remón, Antonin Lévy, (unknown), (unknown), (unknown), Lizza Hendriks, Corinne Faivre‐Finn, Natasha B. Leighl, Martin Reck, M. Pérol	0
2	Innovative, early-phase clinical trials of drug–radiotherapy combinations 2025 ·The Lancet Oncology ·Antonin Lévy, Christophe Massard, Stefan Michiels, Éric Deutsch	3
3	Lung cancer after lung transplantation: Early detection and curative surgery drive long-term survival 2025 ·The Journal of Heart and Lung Transplantation ·(unknown), (unknown), C. Picard, (unknown), Benjamin Coiffard, (unknown), (unknown), (unknown), (unknown), (unknown), V. Boussaud, Antonin Lévy, Vincent de Montpréville, Élie Fadel, Olaf Mercier, (unknown), Jérôme Le Pavec, Vincent Bunel, Pauline Pradère	0
4	Quel traitement local pour la prise en charge des CBNPC oligométastatiques ? 2024 ·Revue des Maladies Respiratoires Actualités ·(unknown), P. Thomas, Jordi Remón, Angela Botticella, Lambros Tselikas, C. Le Péchoux, Antonin Lévy	0
5	New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe 2024 ·The Lancet Regional Health - Europe ·Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, Noemı́ Reguart, Mariano Provencio, Antonin Lévy, Rafał Dziadziuszko, Cecilia Pompili, Massimo Di Maïo, Michael L. Thomas, Alessandro Brunelli, Sanjay Popat, Suresh Senan, Idris Bahce	18
6	Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective 2024 ·The Lancet Regional Health - Europe ·Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, Ronald Damhuis, Noemı́ Reguart, Mariano Provencio, Antonin Lévy, Rafał Dziadziuszko, Cecilia Pompili, Massimo Di Maïo, Michael Thomas, Alessandro Brunelli, Sanjay Popat, Suresh Senan, Idris Bahce	17
7	Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer 2024 ·Cancer Treatment Reviews ·(unknown), Marco Tagliamento, (unknown), (unknown), (unknown), Damien Vasseur, Jordi Remón, Antonin Lévy, Filippo Gustavo Dall’Olio, Benjamin Besse	13
8	Postoperative radiotherapy results in 192 epithelial thymic tumours patients with 10 years of follow-up 2024 ·Radiotherapy and Oncology ·(unknown), (unknown), Angela Botticella, (unknown), (unknown), Benjamin Besse, Élie Fadel, Olaf Mercier, Antonin Lévy, C. Le Péchoux	1
9	Prophylactic Cranial Irradiation for Patients With SCLC—A New Perspective in the Immunotherapy Era 2024 ·Journal of Thoracic Oncology ·Antonin Lévy, Chad G. Rusthoven, Paul D. Brown, C. Le Péchoux, Corinne Faivre‐Finn	4
10	87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience 2024 ·ESMO Open ·(unknown), Carine Ngo, (unknown), Matthieu Faron, (unknown), (unknown), Clémence Henon, (unknown), Antonin Lévy, (unknown)	0
11	Radiotherapy in the management of synchronous metastatic lung cancer 2023 ·Cancer/Radiothérapie ·Jonathan Khalifa, Antonin Lévy, (unknown), S. Thureau, (unknown), C. Le Péchoux, D. Lerouge, N. Pourel, D. Antoni, (unknown), É. Martin, (unknown), P. Giraud, (unknown)	0
12	Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 2023 ·European Journal of Cancer ·(unknown), Marco Tagliamento, Édouard Auclin, Mihaela Aldea, Maxime Frélaut, Antonin Lévy, José Carlos Benítez, Charles Naltet, Pernelle Lavaud, Angela Botticella, (unknown), Nathalie Chaput, Fabrice Barlési, David Planchard, Benjamin Besse	25
13	Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy? 2022 ·Journal for ImmunoTherapy of Cancer ·Roger Sun, (unknown), (unknown), Alexandre Carré, (unknown), Sophie Bockel, (unknown), Antonin Lévy, Cyrus Chargari, Charlotte Robert, Éric Deutsch	22
14	Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review 2019 ·Journal of Thoracic Oncology ·Niccolò Giaj‐Levra, Matteo Giaj Levra, Valérie Durieux, Silvia Novello, Benjamin Besse, Baktiar Hasan, Lizza Hendriks, Antonin Lévy, Anne‐Marie C. Dingemans, Thierry Berghmans	38
15	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres 2018 ·European Journal of Cancer ·Dario Callegaro, Rosalba Miceli, Sylvie Bonvalot, Peter C. Ferguson, D. Strauß, Antonin Lévy, Anthony M. Griffin, Andrew Hayes, Silvia Stacchiotti, C. Le Péchoux, (unknown), Marco Fiore, Angelo Paolo Dei Tos, Henry Smith, Charles Catton, Paolo G. Casali, Jay S. Wunder, Alessandro Gronchi	46
16	Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions 2016 ·European Journal of Surgical Oncology ·Jean‐Baptiste Delhorme, Andrea Fontana, Antonin Lévy, Philippe Terrier, Marco Fiore, Dimitri Tzanis, Dario Callegaro, (unknown), Alessandro Gronchi, Sylvie Bonvalot	14
17	Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer 2015 ·Annals of Oncology ·Éric Deutsch, C. Le Péchoux, Laurence Faivre, Sofía Rivera, Yungan Tao, Jean‐Pierre Pignon, (unknown), Rastilav Bahleda, Désirèe Deandreis, Eric Angevin, C. Hennequin, Benjamin Besse, Antonin Lévy, Jean‐Charles Soria	42
18	Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials 2013 ·Clinical Cancer Research ·Charles Ferté, (unknown), Antoine Hollebecque, Serge Koscielny, Antonin Lévy, Christophe Massard, (unknown), Brian M. Bot, Carlos Gomez‐Roca, Clarisse Dromain, Samy Ammari, Jean‐Charles Soria	130
19	Kaposi’s Sarcoma after Long-Acting Steroids: Time until Remission and Drug Washout 2010 ·Dermatology ·Dany Nassar, N. Schartz, C. Bouché, Antonin Lévy, Delphine Kérob, F. Agbalika, Margaux Lafaurie, Célèste Lebbé	7
20	[Hepatic amebiasis: an unusual clinical presentation]. 1998 ·PubMed ·(unknown), Antonin Lévy, (unknown), (unknown), A Davido	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact